Advertisements

Colpoestriol

Quick links to important sections

Colpoestriol

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Colpoestriol

Quick Facts

Property Description
Active ingredient Estriol (Oestriol, E3)
Form Vaginal Suppository, Vaginal Cream, Oral Tablet
Pharmacological class Estrogen Medication (Hormone Replacement Therapy)
General Purpose Hormone supplementation for estrogen-sensitive tissues
Origin Naturally Occurring (Endogenous) Estrogen Metabolite

What Type of Medicine is Colpoestriol?

Colpoestriol is a single-ingredient pharmaceutical product that supplies the active substance Estriol (E3), and it is classified as an Estrogen Medication used in Hormone Replacement Therapy (HRT). This medication belongs to the family of steroid hormones and is considered a bioidentical compound because its chemical structure is identical to that of the naturally produced human hormone. Estriol is characterized as an atypical and relatively weak estrogen compared to Estradiol, a distinction that is clinically recognized for influencing its specific therapeutic role.

The compound functions as an Estrogen Receptor (ER) agonist, a mechanism supported by pharmacological studies. Its unique action profile, often described as having a short-lived receptor occupancy, differentiates it from other systemic estrogens. Colpoestriol is typically available by prescription only.

Estriol's Composition, Origin, and Available Forms

The active ingredient, Estriol, is a naturally occurring endogenous metabolite derived from the body's breakdown of Estradiol and Estrone. This origin establishes it as a familiar compound within the human endocrine system. The product is frequently formulated for localized administration, most commonly as a vaginal suppository or a vaginal cream, which use a lipophilic base to deliver the hormone directly to the target area. While these localized forms emphasize the vaginal route of administration, Estriol is also manufactured in other dosage forms, such as oral tablets.

General Purpose of Colpoestriol

The general purpose of Colpoestriol is to provide targeted hormone supplementation to support the health and function of tissues that are responsive to estrogen, primarily in postmenopausal women. By locally replenishing Estriol levels, the medication aims to assist in the restoration of tissue integrity, elasticity, and hydration. This action provides relief associated with symptoms of estrogen deficiency, focusing on improving patient comfort and function in specific areas.

Advertisements

What side effects are possible with Colpoestriol?

Possible Side Effects and Safety Information

The safety profile for Estriol, the active ingredient in Colpoestriol, is structured around classifications and warnings detailed in official government regulatory documents. The most frequently documented adverse reactions are categorized as common, affecting up to 10 out of 100 users, and are often local or related to the reproductive system.

Classification Common Adverse Reactions (Examples)
Local Vaginal irritation, pruritus (itching), burning sensation, pelvic pain.
Systemic Headache, breast tenderness or pain, nausea, abdominal discomfort.

Time-related safety patterns indicate that effects such as local irritation and breakthrough bleeding (spotting) are more frequently observed at the start of treatment or during initial dosage adjustments. Regulatory text often groups adverse reactions by System-Organ-Class (SOC), including disorders of the reproductive system, nervous system, and gastrointestinal system.

Serious Safety Considerations

Estriol shares the mandatory serious class risks associated with systemic estrogen therapy, which are documented in official labeling as safety constraints. These less frequent but important risks include an elevated potential for venous thromboembolism (VTE), such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), as well as increased risk of stroke and certain malignancies like endometrial hyperplasia and carcinoma and breast carcinoma.

Safety-Related Restrictions

Official prescribing information includes explicit safety restrictions. The medicine is contraindicated in individuals with a history of or current VTE, known or suspected estrogen-dependent malignant tumors, severe hepatic disease, and undiagnosed abnormal genital bleeding. These constraints define who should not use the medication, based on pre-existing conditions and systemic risks.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information below is based strictly on descriptions found in governmental regulatory documents concerning Estriol overdose.


Documented Manifestations and Emergency Actions

Official regulatory sources describe the clinical presentation of Estriol overdose, particularly following accidental ingestion of high doses, as typically non-life-threatening. Documented manifestations, consistent with excess estrogen exposure, include nausea, vomiting, abdominal pain, and breast tenderness. Withdrawal bleeding or vaginal bleeding may also be observed.

Action Mandated by Regulators Conditions Requiring Urgent Care
Discontinuation of therapy Any suspected overdose event.
Symptomatic and supportive treatment Symptoms persisting after drug discontinuation.
Seek immediate medical attention Accidental ingestion, especially by a child.

No specific antidote is known for Estriol overdose. Management requires the institution of symptomatic and supportive treatment following the discontinuation of the medicine. The official guidance requires patients to seek immediate medical attention or consult a hospital emergency room for assessment, particularly when accidental ingestion by a child has occurred.

Advertisements

Therapeutic Uses of Colpoestriol

Colpoestriol is commonly used to address the symptoms related to estrogen deficiency, particularly those of Genitourinary Syndrome of Menopause (GSM). The use of this medication is aligned with established therapeutic guidelines for managing estrogen deficiency symptoms.

Colpoestriol primarily helps manage conditions characterized by vulvovaginal atrophy, encompassing key symptomatic areas such as chronic dryness, burning, irritation, and painful intercourse (dyspareunia). It is also applied in cases where estrogen deficiency contributes to bothersome urinary issues, including urinary urgency and recurrent urinary tract infections (UTIs).

The primary benefit is relevant for easing symptoms that interfere with daily functioning. This supports patients in managing discomfort and contributes to easing distress related to sexual comfort, improving daily functioning and general well-being during symptomatic periods.

Quick Fact: Relief for Vulvovaginal Atrophy
Primary Focus: Helps address symptom clusters related to persistent vulvovaginal discomfort.
Therapeutic Benefit: Contributes to improved comfort and helps ease the overall symptom load.
Common Scenario: Management of chronic, persistent discomfort in postmenopausal women.
Advertisements

Eligibility and Restrictions for Use

Official Eligibility for Colpoestriol (Estriol)

Official regulatory documentation defines the eligibility for Colpoestriol based on specific population rules, primarily limiting its use to postmenopausal women experiencing local symptoms of estrogen deficiency. Use in children and adolescents is not indicated, as safety and efficacy have not been established.

Absolute Contraindications (Must Not Use)

Individuals who present with certain conditions are contraindicated from using Colpoestriol. This includes patients with a history of or active estrogen-dependent cancers (such as breast cancer or endometrial cancer), undiagnosed genital bleeding, and untreated endometrial hyperplasia. The medicine is also strictly prohibited for those with current or past venous or arterial thromboembolic disease (e.g., blood clots, stroke) or active liver disease.

Physiological Status
Pregnancy is an absolute contraindication.
Use is not recommended during breastfeeding.

Conditional Use (Requires Supervision)

Use is restricted and requires close medical supervision for patients with conditions such as uterine fibroids, hypertension, diabetes mellitus, and gallstones. Patients with cardiac or renal dysfunction must also be carefully monitored due to the potential for fluid retention.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation for Estriol (the active ingredient in Colpoestriol) identifies specific interaction patterns primarily related to the product's metabolism and pharmacodynamic effects.

Documented Pharmacokinetic Interactions

The primary interaction mechanism is rooted in the drug's metabolism by the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with substances that affect this enzyme may alter the plasma concentration of Estriol.

Interaction Type Examples of Interacting Substances Effect on Estriol Concentration
Enzyme Inducers (e.g., Phenobarbital, Rifampin) Herbal products such as St. John’s Wort Documented to decrease Estriol exposure.
Enzyme Inhibitors (e.g., Ketoconazole, Ritonavir) Beverages such as Grapefruit juice Documented to increase Estriol exposure.

Pharmacodynamic Interactions and Restrictions

Official labeling identifies specific combinations that are restricted or that alter the effect of co-administered medicines.

  • Contraindicated Combinations: Co-administration is prohibited with specific combination drug regimens for Hepatitis C that contain ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir.
  • Anticoagulants: Estriol is documented to potentially decrease the anticoagulant activity of coumarin-type agents, such as Warfarin.
  • Thrombogenic Therapies: There is a documented risk of increased thrombogenic activities when Estriol is co-administered with certain other monoclonal antibodies or related therapies.
Advertisements

Mechanism of Action

Colpoestriol, containing the estrogen estriol, functions as a selective estrogen receptor (ER) agonist. Following local administration, the molecule exhibits selective accumulation within urogenital tissues, particularly the vaginal epithelium and lower urinary tract.

At the cellular level, estriol binds to and activates intracellular estrogen receptors ( ERalpha and ERbeta), predominantly ERalpha. Upon binding, the activated hormone-receptor complex dimerizes and translocates to the nucleus. Once in the nucleus, this complex acts as a transcription factor, binding to specific DNA sequences known as Estrogen Response Elements (EREs) in the promoter regions of target genes.

This interaction modulates gene expression, specifically promoting the transcription of genes involved in cell proliferation, differentiation, and tissue maintenance. Downstream cascades include increased synthesis of extracellular matrix components (e.g., collagen), enhanced epithelial cell maturation, and elevated local blood flow.

The system-level physiological consequence of this localized ER activation is the structural and functional maintenance of the vaginal and lower urinary tract epithelia, characterized by increased cell layer thickness and improved tissue turgor.

Advertisements

Dosage and Administration Information

How to Use Colpoestriol (Estriol): Administration Guidelines

Colpoestriol (Estriol) is used according to specific protocols that dictate the route, dose, frequency, and duration of the treatment course. This medication is available for administration via two primary routes: intravaginal (cream or pessary forms) and oral (tablet forms).


Dosing and Scheduling Patterns

The usage protocol is generally structured into two distinct phases: an initial loading period and a maintenance schedule. For the intravaginal route, the initial phase typically involves a daily administration of a measured dose (e.g., 0.5 mg Estriol) for a short period, commonly up to four weeks. This is followed by a reduction to a maintenance dose of the same strength administered only twice per week. The cream form requires a calibrated applicator to ensure the correct dose is measured and delivered.

Oral dosing begins with a higher initial range, such as 4 to 8 mg per day, which is then lowered to a maintenance range of 1 to 2 mg once daily. When taken orally, the total prescribed daily dose must be consumed at one time and swallowed with a drink.


Procedural and Duration Constraints

Specific administration rules govern proper use. Intravaginal doses are typically advised for administration at night before retiring. If an oral dose is missed by more than 12 hours, it must be skipped to avoid a double dose. The overall treatment is intended to use the lowest effective dose for the shortest duration possible, with periodic re-evaluation for tapering or discontinuation recommended at 3 to 6-month intervals.

Advertisements

Recent Clinical Evidence

Colpoestriol: Recent Clinical Evidence

Evidence for use in Genitourinary Syndrome of Menopause (GSM)

Colpoestriol was studied for conditions characterized by vulvovaginal atrophy (VVA), a component of Genitourinary Syndrome of Menopause (GSM). This type of research examined outcomes related to physical discomfort, including patient-reported symptoms like vaginal dryness, burning, irritation, and painful intercourse (dyspareunia).

These studies also monitored physiological changes, or biomarkers, in the context of vaginal health. Research examined outcomes such as the Vaginal Maturation Index (VMI) and measured shifts in vaginal pH levels over defined time intervals, often spanning a short-term duration of around 12 weeks. Studies report how symptoms changed in the observed populations related to these objective measurements. Systematic reviews, which look at many trials together, describe patterns observed in the studies, particularly concerning short-term changes in these indicators.

Long-term Studies and Durability of Response

Clinical trials designed to monitor initial changes in symptoms and biomarkers usually have limited follow-up durations. Core efficacy studies often track these outcomes for short-term periods, typically up to three months. Some comparative studies have explored short-term symptom changes for intermediate periods of up to six months. Research reviews and synthesized data have tracked outcomes across studies for periods up to one year.

Evidence provides context but not individual predictions about long-term use. Data describe patterns related to symptom measurements over these defined time intervals, but long-term outcomes are not fully established. Studies contribute to the broader evidence landscape, but there is limited information for long-term outcomes and the persistence of measured responses beyond the one-year mark.

Evidence in Specific Subgroups

Colpoestriol was evaluated in studies focusing on postmenopausal women presenting with symptoms where intensity may vary. Research examined outcomes in women with varying symptom severity levels, such as those with mild or moderate VVA.

Special population research includes studies monitoring responses in women with specific clinical profiles, such as those with a history of breast cancer who may be receiving concurrent therapies (endocrine treatments). Findings describe group patterns related to these specific cohorts. Results apply only to the populations studied, and data for certain groups remain insufficient. Subgroup findings are uncertain where sample sizes were modest or follow-up durations were limited.

Research Gaps and Areas of Uncertainty

Research contributes to understanding short-term changes related to GSM/VVA, but key limitations exist in the current evidence base. The follow-up durations in many pivotal studies were limited, meaning that long-term outcomes are not fully established for continuous or extended use.

Furthermore, comparative evidence against other available treatments may be lacking, and the certainty remains low when extrapolating findings to populations that were not directly included in the original trials. Evidence quality varies across available studies, and data for certain groups, particularly those with complex medical histories, remain insufficient. Research provides context but not individual predictions, and studies help show what was observed so far within their specific parameters.

Key Studies & References

  1. Menopause: identification and management (NICE guideline NG23)
  2. HRT Guide - British Menopause Society (BMS)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Colpoestriol (FAQ)


Q: How quickly does Colpoestriol start to work after starting treatment?

According to official product information, improvement in symptoms may take several days or even weeks to be noticed. It can sometimes take up to three months for the full benefits described in studies to be observed.

Q: How long can a person safely use Colpoestriol according to official data?

Regulatory documents state that treatment should utilize the lowest effective dose for the shortest duration possible. Official documents advise a periodic re-evaluation for continued need, often at intervals of 3 to 6 months.

Q: What kind of evidence or research supports the use of Colpoestriol?

Studies and official information indicate that evidence supports the use of this medicine for relieving physical discomfort. Researchers examined patient-reported outcomes for symptoms and monitored changes in physical indicators of tissue health, such as vaginal pH and the Vaginal Maturation Index.

Q: Are there any foods or drinks I should avoid while using Colpoestriol?

Regulatory information notes that consuming grapefruit or grapefruit juice may potentially change the amount of this medicine absorbed by the body. No general food-related restrictions are commonly listed in the official product documents.

Q: What kind of interactions are listed for Colpoestriol and herbal supplements?

Official documents note that certain herbal products, such as St. John's Wort, are classified as enzyme inducers. This activity is associated with a potential decrease in the exposure of Estriol (the active ingredient) in the body.

Q: Is Colpoestriol considered a hormone replacement therapy (HRT)?

Yes, Colpoestriol is officially classified as an Estrogen Medication, which belongs to the broader group of medicines known as Hormone Replacement Therapy (HRT).

Q: Is Colpoestriol the same as other vaginal estrogen products?

Official classifications state that Colpoestriol contains the hormone estriol. Estriol is characterized as an atypical and relatively weak estrogen compared to other common estrogens like estradiol, a distinction that influences its specific therapeutic role.

Q: Why do doctors prefer Colpoestriol over oral hormone replacement in some cases?

Because the medication is formulated for localized use, the hormone is released directly where it is needed to relieve local symptoms. This localized administration is characterized by a specific absorption profile that differs from oral methods.

Q: Is it normal to feel a mild burning sensation when first using Colpoestriol?

Yes, regulatory side effect lists note that local irritation or a burning sensation in or around the vagina is a commonly reported side effect. This sensation is often observed when starting treatment and generally improves after the first few weeks of use.

Q: Does Colpoestriol cause weight gain?

Weight gain is listed in regulatory documentation as one of the more common reported adverse reactions associated with the use of this type of medication.

Q: Can using Colpoestriol affect cholesterol levels or blood pressure?

Official labeling identifies high blood pressure (hypertension) and high levels of fats (hypertriglyceridaemia) in the blood as conditions that require medical supervision during use. Patients with these pre-existing conditions are typically monitored closely.

Q: Can women who have had a hysterectomy use Colpoestriol?

The official eligibility criteria primarily focuses on postmenopausal women. Studies have examined the use of estriol in postmenopausal women who have undergone vaginal surgery, which includes hysterectomy.

Q: What happens if I miss a dose of Colpoestriol?

If a dose is missed, regulatory instructions advise administering it as soon as it is remembered. If the dose is more than 12 hours overdue, regulatory protocols advise skipping the missed dose to prevent potential doubling of the next administration.

Q: Do you need a prescription for Colpoestriol?

Yes, Colpoestriol is an estrogen medication and is consistently categorized across regulatory regions as a pharmaceutical product that is available by prescription only.

Q: Does Colpoestriol affect bone density?

As an estrogen medication, the active ingredient belongs to a class of hormones that generally play a structural role in protecting against bone loss. However, official regulatory labeling for this specific medication does not directly make a claim regarding a bone density outcome.

Q: Does Colpoestriol have a black box warning in the US or similar warnings in other countries?

Yes, the medication carries the mandatory serious class risks associated with systemic estrogen therapy, which are documented in official labeling. These warnings address potential elevated risks of venous thromboembolism (VTE), stroke, and certain cancers.

Q: Can Colpoestriol be used by women who are breastfeeding?

Use of the medicine is generally not recommended during breastfeeding. This is because estrogens can potentially be passed into breast milk and may cause a decrease in the milk supply, especially if treatment is started early.

Q: What should I do if the Colpoestriol applicator feels uncomfortable?

Official patient guidance suggests that if an applicator feels uncomfortable during use, it may need to be pushed gently in further. If pain is experienced, official guidance recommends seeking assistance from a healthcare provider.

Q: Do studies show that Colpoestriol improves quality of life?

Official research has included monitoring patient-reported outcomes on the quality of life (QoL) in women using estriol vaginal formulations. This research theme is explored in the context of improving symptoms associated with vaginal health.

Q: Is it common to have some discharge after using Colpoestriol?

Yes, official safety documentation indicates that both increased vaginal discharge and a thick, white vaginal discharge are listed as commonly reported side effects associated with use.

Q: Does Colpoestriol interact with common chronic condition medications like those for diabetes?

While a specific drug-to-drug interaction with common diabetes medications is not directly documented, official labeling lists diabetes mellitus as a conditional use condition. Patients with this condition require careful medical supervision during treatment.

Q: Does alcohol consumption interfere with Colpoestriol?

While regulatory documents do not state a direct interference with the medicine itself, official warnings note that excessive alcohol consumption is a documented factor that can increase the general risk of stroke associated with HRT use.

Q: Can Colpoestriol affect mood or sleep?

Regulatory side effect lists include nervous system changes as possible adverse reactions. These include reports of trouble sleeping, depression, and irritability.

Q: Does the body absorb Colpoestriol into the bloodstream?

Research indicates that estriol is absorbed by the vaginal route. Following insertion, the hormone is absorbed into the surrounding tissue and subsequently into the bloodstream.

Q: If I have allergies, what ingredients in Colpoestriol should I check for?

Official warnings specify that Estriol Cream contains ingredients such as cetyl alcohol and stearyl alcohol. In some formulations, it may contain peanut oil (arachis oil), and patients with known allergies to these substances should verify the ingredients list.

Q: Does Colpoestriol require blood work monitoring?

Official warnings advise patients to inform their doctor if they are scheduled for a blood or urine test. The medication may interfere with the results of certain laboratory tests.

Q: What are the storage requirements for Colpoestriol?

Regulatory information states that the product must be stored at a temperature not above 25 C (77 F) and must not be frozen. It is essential to keep the medicine out of the sight and reach of children.

Q: Is Colpoestriol designed to treat urinary symptoms?

Yes, regulatory documents indicate that the medication is designed to alleviate symptoms of estrogen deficiency. This includes treatment for both vulvo-vaginal complaints and associated lower urinary tract symptoms, such as urinary incontinence and recurrent cystitis.

Q: What is the typical expectation for symptom improvement with Colpoestriol?

According to official product information, improvement in symptoms may take several days or even weeks to be noticed. It can sometimes take up to three months for the full benefits described in studies to be observed.

Q: Is it necessary to use Colpoestriol at the same time every day?

Regulatory protocol advises that intravaginal doses are typically administered at night before retiring. This consistent timing aligns with the need to prevent doubling a dose, which is strictly prohibited if the administration is missed by more than 12 hours.

Q: How is the safety profile of Colpoestriol evaluated in official studies?

The safety profile is evaluated by tracking the frequency and type of adverse reactions by System-Organ-Class. Furthermore, studies monitor patients for the mandatory serious class risks associated with systemic estrogen therapy, such as venous thromboembolism.

Q: Is Colpoestriol safe to use while engaging in sexual activity?

The medicine is described in official documents as relieving discomfort, such as pain during sexual intercourse, associated with estrogen deficiency. Official warnings recommend verifying its use with a doctor if a barrier method of contraception is used, as this product may interact with the device material.

Advertisements

How should Colpoestriol be stored and disposed of?

Storage and Disposal Requirements

Colpoestriol (Estriol 1mg/g cream) must be stored and handled according to specific regulatory guidelines to maintain its stability and ensure safety.


Official Storage

Temperature and Environment

The product must be stored at a temperature not above 25 C (77 F). It is essential that the medicine is not frozen. Do not use the cream after the expiry date shown on the packaging.

Safety

Always keep Colpoestriol out of the sight and reach of children to prevent accidental ingestion or use.


️ Disposal Instructions

Unused or expired medicine must not be disposed of via household waste or wastewater (e.g., flushed down the toilet). To dispose of unwanted or expired product safely, return it to a pharmacist for proper destruction, following environmental protection regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Colpoestriol found in:

A-Z Index: